Capstone Therapeutics (CAPS) Competitors $1.13 -0.03 (-2.59%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CAPS vs. DARE, BCAB, CVKD, MIRA, ENLV, FBLG, AKTX, NAII, SNYR, and PASGShould you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include Dare Bioscience (DARE), BioAtla (BCAB), Cadrenal Therapeutics (CVKD), MIRA Pharmaceuticals (MIRA), Enlivex Therapeutics (ENLV), FibroBiologics (FBLG), Akari Therapeutics (AKTX), Natural Alternatives International (NAII), Synergy CHC (SNYR), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Capstone Therapeutics vs. Its Competitors Dare Bioscience BioAtla Cadrenal Therapeutics MIRA Pharmaceuticals Enlivex Therapeutics FibroBiologics Akari Therapeutics Natural Alternatives International Synergy CHC Passage Bio Capstone Therapeutics (NASDAQ:CAPS) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Does the media refer more to CAPS or DARE? In the previous week, Dare Bioscience had 5 more articles in the media than Capstone Therapeutics. MarketBeat recorded 5 mentions for Dare Bioscience and 0 mentions for Capstone Therapeutics. Dare Bioscience's average media sentiment score of 0.50 beat Capstone Therapeutics' score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Overall Sentiment Capstone Therapeutics Neutral Dare Bioscience Positive Do insiders and institutionals have more ownership in CAPS or DARE? 2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by insiders. Comparatively, 4.8% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is CAPS or DARE more profitable? Company Net Margins Return on Equity Return on Assets Capstone TherapeuticsN/A N/A N/A Dare Bioscience N/A N/A -103.70% Which has stronger valuation and earnings, CAPS or DARE? Capstone Therapeutics has higher revenue and earnings than Dare Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstone Therapeutics$44.88M0.14-$2.56MN/AN/ADare Bioscience$10K2,911.68-$4.05M-$2.14-1.01 Do analysts prefer CAPS or DARE? Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 362.96%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Capstone Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dare Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CAPS or DARE? Capstone Therapeutics has a beta of -0.81, indicating that its share price is 181% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. SummaryDare Bioscience beats Capstone Therapeutics on 8 of the 12 factors compared between the two stocks. Get Capstone Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.47M$3.17B$5.81B$10.01BDividend YieldN/A2.28%5.29%4.53%P/E RatioN/A21.3475.6926.28Price / Sales0.14469.04539.36121.13Price / CashN/A45.5837.2059.76Price / Book-0.0610.0511.506.41Net Income-$2.56M-$53.33M$3.28B$270.56M7 Day Performance-4.24%2.18%1.30%3.01%1 Month Performance-14.39%11.91%11.25%9.74%1 Year PerformanceN/A14.14%59.54%26.68% Capstone Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstone TherapeuticsN/A$1.13-2.6%N/AN/A$6.47M$44.88M0.0038News CoverageGap UpDAREDare Bioscience1.9209 of 5 stars$2.02-0.5%$12.00+494.1%-37.7%$27.23M$10K-0.9430BCABBioAtla1.5251 of 5 stars$0.46+8.5%$5.00+997.7%-64.9%$26.75M$11M-0.4160News CoverageAnalyst UpgradeCVKDCadrenal Therapeutics3.1314 of 5 stars$12.96-2.5%$32.00+146.9%+70.8%$26.53MN/A-1.464Gap DownMIRAMIRA Pharmaceuticals2.6707 of 5 stars$1.37-2.1%$17.00+1,140.9%-11.0%$26.12MN/A-2.802Short Interest ↓ENLVEnlivex Therapeutics3.4843 of 5 stars$1.05+1.0%$10.00+852.4%-18.1%$24.83MN/A-1.5970News CoverageFBLGFibroBiologics2.4888 of 5 stars$0.59-4.9%$13.00+2,103.0%-72.8%$24.72MN/A-1.6410News CoverageAKTXAkari Therapeutics3.0765 of 5 stars$0.76-5.8%$5.00+557.9%-74.4%$24.45MN/A0.009News CoverageAnalyst ForecastShort Interest ↑Gap UpNAIINatural Alternatives InternationalN/A$3.88+8.2%N/A-50.1%$23.05M$113.80M-2.79290Positive NewsSNYRSynergy CHC3.8236 of 5 stars$2.42+14.2%$10.00+313.2%N/A$22.85M$34.83M6.3740High Trading VolumePASGPassage Bio2.8944 of 5 stars$7.13+3.3%$91.75+1,186.8%-49.4%$22.66MN/A-0.39130 Related Companies and Tools Related Companies DARE Alternatives BCAB Alternatives CVKD Alternatives MIRA Alternatives ENLV Alternatives FBLG Alternatives AKTX Alternatives NAII Alternatives SNYR Alternatives PASG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
